glucose-dependent raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-07-28. Anything still debated is marked as such rather than presented as settled.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 or 280 nanometres is widely used to assess purity and to resolve related impurities. Liquid chromatography coupled to mass spectrometry confirms identity through the protonated molecular ion and fragment ions formed in tandem experiments. Capillary electrophoresis and peptide mapping after enzymatic digestion supply complementary information on charge variants and modification sites. Circular dichroism and nuclear magnetic resonance can report on secondary structure in solution. Absolute quantification usually depends on an external standard, and reported purity depends on the detection wavelength and integration parameters chosen.
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
| Property | Value | Notes |
|---|---|---|
| Chemical class | GLP-1 receptor agonist peptide | Mimics endogenous incretin signaling |
| Molecular mass | Approximately 4114 Da | Modified 31-amino-acid backbone |
| Appearance | White to off-white powder | Typical of lyophilized peptide material |
| Solubility | Soluble in water | Behavior depends on salt form and buffer |
| Elimination half-life | About one week | Supported by albumin binding and protease resistance |
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.
The sequence incorporates alpha-aminoisobutyric acid at position 8, replacing the alanine found in the natural hormone. This substitution blocks the primary DPP-4 recognition site and contributes most of the enzymatic stability. Albumin binding further protects the peptide and reduces the frequency of administration required to maintain active plasma levels. Because the fatty acid chain increases lipophilicity, the compound is formulated as a solution rather than a simple aqueous buffer. Researchers describe the design as an incremental optimization of earlier GLP-1 analogs rather than a wholly new scaffold.
Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
=== Trump accounts and contribution pilot program === The law creates Trump accounts, a type of tax-advantaged savings investment account. Any individual is allowed to contribute to a child's account, up to $5,000 per year per child. Employers are allowed to contribute to their employees' accounts and their employees' children's accounts, up to $2,500 per year. Contributions by an employer count against the $5,000 annual limit per child, but contributions by the federal government do not. As an exception to the annual limit, tax-exempt organizations are allowed to contribute an unlimited amount into a child's account. Contributions into a child's account are allowed until the end of the end of the year in which the child turns 18. The federal government will contribute $1,000 into a Trump account for each U.S. citizen child with a social security number who was born between January 1, 2025, and December 31, 2028. Funds in the account must be invested in mutual funds or exchange-traded funds that mirror the S&P 500 or another U.S. stock index. Investment earnings are tax-deferred. A child with a qualified disability is allowed to rollover the funds into an ABLE account when they reach age 17. For other children, rollovers and withdrawals from the account are allowed starting on the January 1 of the year in which the child turns age 18. When the child reaches age 18, the funds will be rolled into a traditional IRA.
In June 2020, TikTok users and K-pop fans "claimed to have registered potentially hundreds of thousands of tickets" for Donald Trump's campaign rally in Tulsa, Oklahoma through communication on TikTok, contributing to "rows of empty seats" at the event. Later, in October 2020, an organization called TikTok for Biden was created to support then-presidential candidate Joe Biden. After the election, the organization was renamed to Gen-Z for Change. On 10 August 2020, Emily Jacobssen wrote and sang "Ode to Remy", a song praising the protagonist from Pixar's 2007 computer-animated film Ratatouille. The song rose to popularity when musician Daniel Mertzlufft composed a backing track to the song. In response, began creating a "crowdsourced" project called Ratatouille the Musical. Since Mertzlufft's video, many new elements including costume design, additional songs, and a playbill have been created. On 1 January 2021, a full one-hour virtual presentation of Ratatouille the Musical premiered on TodayTix. It starred Titus Burgess as Remy, Wayne Brady as Django, Adam Lambert as Emile, Kevin Chamberlin as Gusteau, Andrew Barth Feldman as Linguini, Ashley Park as Colette, Priscilla Lopez as Mabel, Mary Testa as Skinner, and André De Shields as Ego. A viral TikTok trend known as "devious licks" involves students vandalizing or stealing school property and posting videos of the action on the platform. The trend has led to increasing school vandalism and subsequent measures taken by some schools to prevent damage. Some students have been arrested for participating in the trend.
=== Further clinical studies of radiolabeled somatostatin receptor antagonists === Ga-NODAGA-JR11 had entered further clinical studies as an imaging agent, while Lu-DOTA-JR11 had similar research done as a therapeutic agent, as JR11 has a high binding affinity for ssrt2 subtype receptors which are highly expressed on the surface of tumor cells. Gallium-containing agonists had already been established as an imaging agent. Lutetium-containing agonists were used as a therapeutic agent in peptide receptor radionuclide therapy, due to the lower energy electrons emitted, and γ-emission causing easier dose adjustment to patient characteristics to avoid renal damage. The NODAGA chelator was used over DOTA in Gallium antagonists due to higher binding affinity, while no Lu-NODAGA compounds were developed due to established usage of Lu-DOTA derivative agonist drugs, and poor uptake compared to DOTA, which is reverse that of the gallium-containing antagonists.
As President, Johnson steadfastly pursued the Gemini and Apollo programs, promoting them as Kennedy's legacy to the American public. One week after Kennedy's death, he issued Executive Order 11129 renaming the Cape Canaveral and Apollo launch facilities after Kennedy.
Inspection focuses on the face and particularly on the tongue, including analysis of the tongue size, shape, tension, color and coating, and the absence or presence of teeth marks around the edge. Auscultation refers to listening for particular sounds (such as wheezing). Olfaction refers to attending to body odor. Inquiry focuses on the "seven inquiries", which involve asking the person about the regularity, severity, or other characteristics of: chills, fever, perspiration, appetite, thirst, taste, defecation, urination, pain, sleep, menses, leukorrhea. Palpation which includes feeling the body for tender A-shi points, and the palpation of the wrist pulses as well as various other pulses, and palpation of the abdomen.
Sources: en.wikipedia.org
denotes the Kronecker delta. The physical interpretation of the various terms in the above master equation is straight forward: the terms on the first line describe the growth of fibrils via monomer addition with rate constant
=== Relationships === Carrey dated singer Linda Ronstadt for eight months in 1983. On March 28, 1987, Carrey married former actress and Comedy Store waitress Melissa Womer. The couple had one daughter. Carrey and Womer divorced in 1995. On September 23, 1996, Carrey married his Dumb and Dumber co-star Lauren Holly; this second marriage lasted less than a year. From 1999 to 2000, Carrey was engaged to his Me, Myself & Irene co-star Renée Zellweger. In 2002, he was in a relationship with January Jones. In 2005, Carrey met model and actress Jenny McCarthy, and he made public in June 2006 that they were in a romantic relationship. They ended it in April 2010, with McCarthy noting in October 2010 that they had remained good friends. In early 2011, Carrey was seen holding hands with America's Next Top Model contestant Anchal Joseph, leading to speculation that the two were dating. In 2012, Carrey met Cathriona White, a makeup artist from County Tipperary, Ireland. They dated between 2012 and 2015. On September 28, 2015, White was found dead from a prescription drug overdose; the death was ruled a suicide by the Los Angeles County Medical Examiner. Carrey was a pallbearer at her funeral in Cappawhite, Ireland. In January 2019 when Carrey attended the Golden Globes 2019 Party, he was accompanied by his then-girlfriend Ginger Gonzaga. The couple split after less than a year of dating.
Additionally, one trial aimed to assess its role in preventing actinic keratosis in organ transplant recipients. Further trials were pursued for the first two conditions, while results for the latter three were not published. Following the initial trials, research efforts centered on erythropoietic protoporphyria, and due to the epidemiology of the condition. Clinuvel secured orphan drug for afamelanotide in both the US and the EU by 2010. The first approval of afamelanotide came in May 2010 from the Italian Medicines Agency (AIFA, or Agenzia Italiana del Farmaco), followed by the European Medicines Agency (EMA) in January 2015. Both approvals were for the treatment of erythropoietic protoporphyria. The US Food and Drug Administration (FDA) granted approval in October 2019 for the use of afamelanotide as a medication to alleviate pain caused by sun exposure in individuals with erythropoietic protoporphyria. This decision was largely based on three trials involving 244 adults aged 18–74 across 22 sites in the US and Europe, which had a focus on pain-free hours in sunlight, outdoor hours under varying light conditions, and side effects. The FDA designated it as a first-in-class medication, meaning it had a novel mechanism different from previously approved medications. Between 2022 and 2023, trials were outlined to study the effects of afamelanotide on xeroderma pigmentosum and variegate porphyria, along with two additional trials exploring its impact on vitiligo. According to the register, as of April 2025, most of these trials are currently in the recruitment phase.
=== Humoral hypercalcemia of malignancy === PTHrP is related in function to parathyroid hormone (PTH). When a tumor secretes PTHrP, this can lead to hypercalcemia. As this is sometimes the first sign of the malignancy, hypercalcemia caused by PTHrP is considered a paraneoplastic phenomenon. PTHrP is responsible for most cases of humoral hypercalcemia of malignancy. PTHrP shares the same N-terminal end as parathyroid hormone and therefore it can bind to the same receptor, the Type I PTH receptor (PTHR1). PTHrP can simulate most of the actions of PTH including increases in bone resorption and distal tubular calcium reabsorption, and inhibition of proximal tubular phosphate transport. PTHrP lacks the normal feedback inhibition as PTH. However, PTHrP has a less sustained action than PTH on PTHR1 activation, which may explain at least in part its reduced ability to stimulate 1,25-dihydroxyvitamin D (1,25(OH)2 vitamin D) production and indirectly intestinal calcium absorption through an action to increase circulating levels of 1,25(OH)2 vitamin D.
Other traditional triglyceride lipases (EC 3.1.1.3) include Lipase member N, DDHD2, PNLIPRP3, PNPLA4, and PNPLA5. In addition, there are various other non-traditional lipases including Monoacylglycerol lipases (eg: MGLL, ABHD2, and ABHD6), and Diacylglycerol lipases (eg: DAGLA, DAGLB, and ABHD11). Not all lipase-family proteins function as lipases in humans. Some like Lipase member H and Lipase member I function as phospholipases, while others like pancreatic lipase related protein 1 (PNLIPRP1), LIPJ, LIPK, and LIPM do not (yet) have a well established function as an enzyme.
Sources: en.wikipedia.org
According to Wayman, Nagarjuna's explanation is as follows: "the three defilements – nescience, craving, and indulgence – give rise to the two karmas – motivations and gestation – and that these two give rise to the seven sufferings – perception, name-and-form, six sense bases, contact, feelings, re-birth, and old age and death." Vasubandhu's presentation is fully consistent with Nagarjuna's: "nescience, craving, and indulgence are defilement; motivations and gestations are karma; the remaining seven are the basis (asraya) as well as the fruit (phala). As outlined by Wayman, Asanga's Abhidharma-samuccaya divides the nidanas into the following groups:
=== Pharmacokinetics === After being ingested, clonidine is absorbed into the blood stream rapidly with an overall bioavailability around 70–80%. Peak concentrations in human plasma occur within 60–90 minutes for the "immediate release" (IR) version of the drug, which is shorter than the "extended release" (ER/XR) version. Clonidine is fairly lipid soluble with the logarithm of its partition coefficient (log P) equal to 1.6; to compare, the optimal log P to allow a drug that is active in the human central nervous system to penetrate the blood brain barrier is 2.0. Less than half of the absorbed portion of an orally administered dose will be metabolized by the liver into inactive metabolites, with roughly the other half being excreted unchanged by the kidneys. About one-fifth of an oral dose will not be absorbed, and is thus excreted in the feces. Work with liver microsomes shows in the liver clonidine is primarily metabolized by CYP2D6 (66%), CYP1A2 (10–20%), and CYP3A (0–20%) with negligible contributions from the less abundant enzymes CYP3A5, CYP1A1, and CYP3A4. 4-hydroxyclonidine, the main metabolite of clonidine, is also an α2A agonist but is non lipophilic and is not believed to contribute to the effects of clonidine since it does not cross the blood–brain barrier. Measurements of the half-life of clonidine vary widely, between 6 and 23 hours, with the half-life being greatly affected by and prolonged in the setting of poor kidney function. Variations in half-life may be partially attributable to CYP2D6 genetics.
The "vagusstuff" (as Loewi called it) causing the myotropic (muscle enhancing) effects was later identified to be acetylcholine and norepinephrine. Loewi won the Nobel Prize for his discovery. Recent work in endocrinology focuses on the molecular mechanisms responsible for triggering the effects of hormones. The first example of such work being done was in 1962 by Earl Sutherland. Sutherland investigated whether hormones enter cells to evoke action, or stayed outside of cells. He studied norepinephrine, which acts on the liver to convert glycogen into glucose via the activation of the phosphorylase enzyme. He homogenized the liver into a membrane fraction and soluble fraction (phosphorylase is soluble), added norepinephrine to the membrane fraction, extracted its soluble products, and added them to the first soluble fraction. Phosphorylase activated, indicating that norepinephrine's target receptor was on the cell membrane, not located intracellularly. He later identified the compound as cyclic AMP (cAMP) and with his discovery created the concept of second-messenger-mediated pathways. He, like Loewi, won the Nobel Prize for his groundbreaking work in endocrinology.
Spruance, as it turned out, was acting appropriately to the Japanese plans that called for a diversion to draw the fleet far away so there would be a great opportunity for land-based Japanese planes to also augment the carrier aircraft to attack Spruance's fleet. Before daybreak, Spruance suggested that if the daybreak searches revealed no targets, the bombers could be sent to crater the airfields on Rota and Guam. However, the fleet's contact-fused bombs had been largely used up in the earlier strikes, and Mitscher was left with only the armor-piercing bombs needed to combat the Japanese fleet, so he informed Spruance he could not launch such strikes. As the morning broke, TF 58 launched search aircraft, combat air patrols (CAP) and anti-submarine patrols and then turned the fleet west to gain maneuvering room from the islands. The U.S. Navy had developed a sophisticated air control system, which vectored CAP fighters by radar to intercept enemy bombers well before they reached the fleet. Any attackers that got through the CAP would then face a "gun line" of screening battleships and cruisers that would put up devastating barrages of VT-fuzed anti-aircraft fire before the attackers reached the aircraft carriers.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and cleared quickly. Semaglutide carries a position 8 substitution that blocks that cleavage and a fatty diacid chain that binds albumin. Together these changes extend its circulating half-life to about one week.
Yes. Stimulation of insulin secretion is glucose-dependent, meaning the effect is larger when blood glucose is high and minimal when it is normal. This property separates GLP-1 receptor agonists from agents that drive insulin release regardless of glucose level.
Receptor expression in hypothalamic and brainstem regions is well documented, and reduced energy intake is consistently observed. The relative contribution of central versus peripheral signaling to total weight change is still an open question addressed by ongoing research.
Filtering removes particulate matter that can block columns or scatter light. A 0.22 micrometre membrane is typical, and the filter material should be checked for peptide adsorption.